G-protein-coupled estrogen receptor agonist suppresses airway inflammation in a mouse model of asthma through IL-10*

Masamichi Itoga1)2), Yasunori Konno1)3), Yuki Moritoki1), Yukiko Saito1), Wataru Ito1)4), Mami Tamaki1), Yoshiki Kobayashi1)5), Hiroyuki Kayaba1)2), Yuta Kikuchi1), Junichi Chihara6), Masahide Takeda1)7);, Shigeharu Ueki1)‡, Makoto Hirokawa1)

1)Department of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan
2)Department of Clinical Laboratory Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki 036-8562, Japan
3)Division of Dentistry and Oral Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan
4)Nagareyama Tobu Clinic, 909-1 Nazukari, Nagareyama City, Chiba, 270-0145, Japan
5)Department of Otolaryngology, Kansai Medical University, 2-5-1 Shin-machi, Hirakata City, Osaka, 573-1010, Japan
6)Soseikai General Hospital, 101 Shimotoba Hiroosacho, Fushimi-ku, Kyoto City, Kyoto, 612-8473, Japan
7)Department of Cardiovascular and Respiratory Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan

*Funding provided in part by Grants-in-Aid for Scientific Research (C) (24590952 (Y. Moritoki), 13383320 (S. Ueki)) and Grants-in-Aid for Young Scientists (23791097 and 26860743 (M. Takeda), 24790547 (Y. Kobayashi)) supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Address correspondence and reprint requests to: ‡Dr. Shigeharu Ueki or Dr. Masahide
Takeda, Department of General Internal Medicine and Clinical Laboratory Medicine,
Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543 Japan.
E-mail: ueki-shige@nifty.com or takeda-56@hos.akita-u.ac.jp
Phone: +81-18-884-6209, Fax: +81-18-884-6209

Short title: GPER agonist suppresses asthma through IL-10

Key words: asthma, airway inflammation, estrogen, G-protein-coupled estrogen receptor
Abstract

Estrogen influences the disease severity and sexual dimorphism in asthma, which is caused by complex mechanisms. Besides classical nuclear estrogen receptors (ER\(\alpha/\beta\)), G-protein-coupled estrogen receptor (GPER) was recently established as an estrogen receptor on the cell membrane. Although GPER is associated with immunoregulatory functions of estrogen, the pathophysiological role of GPER in allergic inflammatory lung disease has not been examined. We investigated the effect of GPER-specific agonist G-1 in asthmatic mice. GPER expression in asthmatic lung was confirmed by immunofluorescent staining. OVA-sensitized BALB/c and C57BL/6 mice were treated with G-1 by daily subcutaneous injections during an airway challenge phase, followed by histological and biochemical examination. Strikingly, administration of G-1 attenuated airway hyperresponsiveness, accumulation of inflammatory cells, and levels of Th2 cytokines (IL-5 and IL-13) in BAL fluid. G-1 treatment also decreased serum levels of anti-OVA IgE antibodies. The frequency of splenic Foxp3\(^{+}\)CD4\(^{+}\) regulatory T cells and IL-10-producing GPER\(^{+}\)CD4\(^{+}\) T cells was significantly increased in G-1-treated mice. Additionally, splenocytes isolated from G-1-treated mice showed greater IL-10 production. G-1-induced amelioration of airway inflammation and IgE production were abolished in IL-10-deficient mice. Taken together, these results indicate that extended GPER activation negatively regulates the acute asthmatic condition by altering the IL-10-producing lymphocyte population. The current results have potential importance for understanding the mechanistic aspects of function of estrogen in allergic inflammatory response.
Introduction

Asthma is known to be a sexually dimorphic disease in terms of severity; women have more severe asthma than men with increased airway hyperresponsiveness (AHR) [1,2,3]. Indeed, experimental evidence including ours indicates that female mice are more susceptible to development of allergic airway inflammation, AHR, and airway remodeling [4,5]. A recent clinical study using cluster analysis revealed a female-dominant phenotype, indicating the heterogeneity of asthma and different pathophysiology in female asthmatics [6].

A role for estrogen in modulating asthma is deduced from the natural history of asthma. Coincident with the onset of puberty and increasing levels of circulating estrogen, asthma becomes significantly more common in women than in men, particularly during the reproductive years and pregnancy [7]. Another observation regarding the contribution of estrogen is that female asthmatics can be affected by pregnancy, menstruation cycle, menopause, and hormone replacement therapy [8]. Many epidemiological and clinical studies have shown that estrogen likely contributes to disease severity and development of asthma, although the results are not consistent. In contrast, several studies have indicated that supplemental estrogen is successfully used as a steroid-sparing agent in women with severe asthma [9,10]. The influence of estrogen has been investigated in animal models of asthma with both favorable and unfavorable results [11]. Therefore, understanding the functional mechanism of estrogen in asthmatics is potentially important to achieve future personalized treatment.

Estrogen has a multitude of biological effects not only on the female reproductive system but also on the immune system. The actions of estrogen have been traditionally described as occurring through one of the two classical nuclear estrogen receptors, estrogen receptor (ER) α and ERβ, which function as ligand-dependent transcription factors that bind directly to estrogen response elements in the promoter regions of genes. In addition to the long-term regulation of gene expression, estrogen has also been shown to mediate many rapid biological responses. An estrogen-binding site was found on the cell membrane [12,13], and G-protein-coupled receptor (GPCR) was identified as an estrogen-binding membrane receptor. G-protein-coupled estrogen receptor (GPER) is abundantly expressed not only in the brain and cardiovascular systems but also in the lungs [14,15]. In addition to the fact that ERs and GPER possess different signaling...
mechanisms, their actions are thought to be independent by several measures of
difference, such as expression, binding affinity to estrogen, and biological functions. A
GPER-selective agonist has been linked to a variety of pathological and physiological
events regulated by estrogen action, including female reproductive cancer and the renal
and cardiovascular systems [16]. To date, several studies have indicated the
immunoregulatory functions of GPER [17,18,19,20,21,22], although the roles of GPER
in allergic inflammatory diseases have yet to be elucidated.

Given this background, we aimed to investigate the role of GPCR in asthmatic
mice using GPER-specific agonist G-1. Our data indicated that extended GPER
activation negatively regulated the Th2-mediated airway inflammatory response in an
interleukin (IL)-10-dependent manner.
Materials and methods

Animals
Female BALB/c, C57BL/6, and IL-10 KO mice at 8–10 weeks of age were purchased from Charles River Japan, Inc. (Yokohama, Japan). These mice were maintained on ovalbumin (OVA)-free diets. All experimental animals used in this study were housed under constant temperature and light cycles, and under a protocol approved by the Institutional Animal Care and Use Committee of Akita University Graduate School of Medicine and Faculty of Medicine.

Sensitization and airway challenge
Mice were immunized by intraperitoneal injection of 20 µg OVA (Grade V; Sigma-Aldrich, St. Louis, MO) emulsified in 2.25 mg of alum (Imject Alum; Pierce, Rockford, IL) in a total volume of 100 µl on Days 0 and 14. Mice were challenged via the airways with 1% OVA in saline for 20 min on Days 28, 29, and 30 by ultrasonic nebulization (Fig. 1). Lung resistance and dynamic lung compliance to methacholine (Sigma-Aldrich) were assessed 48 hours after the last challenge, and tissues and cells were obtained for further assays [23,24].

Administration of G-1
G-1 (Cayman Chemical Company, Ann Arbor, MI) was purchased [25]. Mice received subcutaneous injections of G-1 5 µg daily [26,27], from Days 27 to 31 (Fig. 1). G-1 was dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and adjusted to a density of 5 µg/100 µL/mouse.

Evaluation of AHR
Lung resistance and dynamic lung compliance to methacholine were measured using an invasive system, as previously described [28]. Briefly, mice were deeply anesthetized, and tracheotomies were performed. The mice were then placed in an Elan Series Mouse RC Site chamber (Buxco Electronics, Wilmington, NC) and ventilated mechanically. Once baseline data were established, saline and an increasing dose of nebulized methacholine were administered. At each dose, airflow changes in the sealed chamber and pressure changes in the airway were analyzed with BioSystem XA.
software (Buxco Electronics) for 3 minutes. Lung resistance and dynamic lung
compliance for each methacholine dose were expressed as a percentage change from
baseline level.

**Collection of bronchoalveolar lavage fluid and measurement of cytokines**
The lungs were lavaged through the tracheal tube with saline (1 mL, 2 times, 
37°C). The volume of collected bronchoalveolar lavage (BAL) fluid was measured in
each sample, and the number of BAL cells was counted. Cytospin slides were stained
with May-Giemsa, and at least 300 cells were differentiated in a blinded fashion under
light microscopy. Cytokine concentrations in the BAL fluid supernatants were measured
by means of enzyme-linked immunosorbent assay (ELISA). Colorimetric measurement
was performed according to the manufacturer’s instructions. The minimum detectable
doses (MDD) are 2 pg/mL of mouse IL-4 and interferon gamma (IFN-γ), 7 pg/mL of
IL-5, 1.5 pg/mL of IL-13, and 3 pg/mL of eotaxin, respectively (R&D Systems,
Minneapolis, MN).

**Measurement of serum levels of total and OVA-specific immunoglobulin E (IgE) antibodies**
Total and OVA-specific IgE antibody levels were measured by means of ELISA
(Bethyl Laboratories, Inc., Montgomery, TX) 48 hours after the last airway challenge
[29].

**Histological evaluation**
The lungs were inflated through a tracheal tube with 2 mL of air and fixed in 10%
formalin, and lung tissue was embedded in paraffin. Tissue sections with a thickness of
4 µm were affixed to microscope slides and deparaffinized. The slides were stained with
hematoxylin and eosin (H&E) and examined under light microscopy to detect
inflammatory cell infiltrates. In H&E lung sections, the numbers of inflammatory cells
per square millimeter in the peribronchial areas were analyzed using the National
Institutes of Health (NIH) Image Analysis system [30]. Serial sections were also stained
with Periodic acid-Schiff (PAS) and Masson trichrome (MT). For histopathologic
analysis, sample regions were randomly selected in a coded manner.
**Splenocyte culture for cytokine production**

The culture of splenocytes was performed as described previously [31]. Briefly, on Day 32, mice were sacrificed, the spleens were excised, and the splenocytes were disaggregated. Splenic mononuclear cells were isolated by density gradient using Histopaque-1083 (Sigma-Aldrich), and the washed cells were resuspended at $8 \times 10^6$/ml in complete medium consisting of Roswell Park Memorial Institute 1640 (RPMI 1640) (Life Technologies, Carlsbad, CA) with 10% heat-inactivated fetal bovine serum (FCS) (Life Technologies), 50 ng/mL phorbol myristate acetate (PMA) (Sigma-Aldrich), and 10 mM A23187 (Sigma-Aldrich). The cells were then cultured for 2 days at 37°C in a 5% CO$_2$ humidified atmosphere. For the cytokine assay, the culture supernatants of the cells were collected at 2 days. The levels of IL-10 in the supernatants were measured using ELISA.

**Flow cytometry**

Splenocytes were prepared from the C57BL/6 mice after sensitization and airway challenge with OVA in the presence or absence of G-1 administration. Briefly, on Day 32, splenic mononuclear cells were isolated as shown above. The cells were pre-incubated with an anti-mouse FcR blocking reagent and then incubated at 4°C for cell surface staining with a combination of fluorochrome-conjugated antibodies: 1), PE-Cy5-conjugated anti-TCR$\beta$ (BioLegend, San Diego, CA), PE-Cy7-conjugated ant-NK1.1 (BioLegend), PE-CF594-conjugated anti-CD8a (BD Biosciences, San Jose, CA), and Alexa Fluor 488-conjugated anti-CD4 (BioLegend). Then, the cells were washed, permeabilized with BD Cytofix/Cytoperm (BD Biosciences), and stained with PE-conjugated anti-IL-10 (BioLegend) to detect intracellular IL-10. 2), PE-Cy5-conjugated anti-TCR$\beta$ (BioLegend, San Diego, CA), PE-Cy7-conjugated ant-NK1.1 (BioLegend), PE-Cy7-conjugated anti-CD8a (BioLegend), PE-CF594-conjugated anti-CD4 (BD Biosciences), and GPR30 (N-15)-R Antibody (Santa Cruz Biotechnology, Santa Cruz, CA) with subsequent staining by Alexa Fluor 488-conjugated goat anti-rabbit immunoglobulin G (IgG) (Invitrogen, Grand Island, NY). Then, the cells were washed, permeabilized with BD Cytofix/Cytoperm (BD Biosciences), and stained with PE-conjugated anti-IL-10 (BioLegend) to detect intracellular IL-10. 3), PE-Cy5-conjugated anti-TCR$\beta$
(BioLegend, San Diego, CA), PE-Cy7-conjugated ant-NK1.1 (BioLegend), PE-Cy7-conjugated anti-CD8a (BioLegend), and PE-CF594-conjugated anti-CD4 (BD Biosciences). Then, the cells were washed, permeabilized with BD Cytofix/Cytoperm (BD Biosciences), and stained with Alexa Fluor 488-conjugated IL-10 (BioLegend) to detect intracellular IL-10, and stained with PE-conjugated anti-Foxp3 (BioLegend) to direct intracellular Foxp3.

Multicolor flow analyses were performed using the Cytomics FC 500 (Beckman Coulter, Inc., Brea, CA) flow cytometer to allow for 5-color analysis. Acquired data were analyzed with FlowJo software (Tree Star, Inc., Ashland, OR).

**Statistical analysis**

Two groups of data were compared using the Mann-Whitney U test. The P value for significance was set at less than 0.05. All results were expressed as the mean ± SEM.
Results

GPER expression in lung tissue

The expression of GPER in human immune cells (monocytes, macrophages, eosinophils, B cells, T cells) has been demonstrated [22,32]. GPER mRNA expression has been reported in the lungs of the C57BL/6 mouse strain [15,33]. We first examined the expression of GPER in the asthmatic lung tissue using immunofluorescence imaging. As shown in S1 Fig., GPER was expressed in the lung both in BALB/c and C57BL/6 mice.

Administration of G-1 ameliorated AHR in BALB/c mice

Increased AHR induced by an immunologically non-specific stimulant such as methacholine is a fundamental feature of asthma. OVA-induced asthmatic mice develop AHR in response to increasing doses of inhaled methacholine. We examined the changes in airway resistance (reflecting AHR in large airways) and dynamic lung compliance (reflecting AHR in small airway) to assess whether G-1 administration influences AHR. As shown in Fig. 2, in response to inhaled methacholine, asthmatic mice treated with phosphate buffered saline (PBS) had an increase in airway resistance and a decrease in lung compliance. In contrast, these responses to methacholine were significantly attenuated in G-1-treated asthmatic mice, indicating the suppression of AHR.

Administration of G-1 attenuated inflammatory cell accumulation in BAL fluid in BALB/c mice

Since airway inflammation leads to development of AHR, we next investigated inflammatory cell infiltration into the airway by histological examination of H&E staining. In G-1-treated mice, inflammatory cells in the peribronchial areas were significantly decreased compared with those of non-treated BALB/c mice (Fig. 3A, upper panels, Fig. 3B). Goblet cells in airway epithelium and collagen deposition were also examined by PAS and MT staining, respectively. As shown in Fig. 3A (lower panels), goblet cell hyperplasia and lung fibrosis were also attenuated in G-1-treated mice. The numbers and types of inflammatory cells in the airways were determined in BAL fluid 48 h after the last of the three consecutive allergen challenges (Fig. 3C).
Non-treated mice showed a marked increase in the number of eosinophils and lymphocytes in BAL fluid, whereas G-1 treatment significantly reduced the number of eosinophils and lymphocytes. These findings indicate that administration of G-1 suppress allergic airway inflammation.

**Administration of G-1 reduced levels of cytokine, chemokine, and OVA-specific IgE in BALB/c mice**

Since G-1 attenuated OVA-induced lung inflammation, we measured levels of Th1 and Th2 cytokines (IL-4, 5, and 13 and INF-γ) and an eosinophil-driving chemokine eotaxin (CCL11) in BAL fluid using ELISA. Administration of G-1 significantly reduced the levels of IL-5 and IL-13 in BAL fluid compared with non-treated mice (Fig. 4A). We also assessed the serum levels of total and OVA-specific IgE. As shown in Fig. 4B, OVA-specific IgE was significantly reduced in G-1-treated asthmatic mice. These data suggest that G-1 administration attenuates Th2 cytokines in lung and antigen-specific B cell response in this asthmatic model of mice.

**Administration of G-1 attenuated allergic airway inflammation in C57BL/6 mice**

BALB/c mice are thought to be immunologically Th2 shifted and thus used in asthmatic models more frequently than C57BL/6 mice. To examine whether the G-1-induced anti-inflammatory effects are limited to the Th2-shifted strain, we performed the same experiment using C57BL/6 mice. In H&E-stained lung sections, inflammatory cells in the peribronchial areas were significantly decreased in G-1-treated C57BL/6 mice (Fig. 5A, B). PAS-stained goblet cells in airway epithelium and MT-stained collagen were decreased in G-1-treated mice (Fig. 5A), similar to those in G-1-treated BALB/c mice (Fig. 3A). G-1 administration significantly reduced the number of total cells, eosinophils, and lymphocytes in BAL fluids of C57BL/6 mice (Fig. 5C). Administration of G-1 significantly reduced the levels of IL-5 and IL-13 in BAL fluid and serum levels of total and OVA-specific IgE antibodies in C57BL/6 mice, as well (Fig. 6A, B). These findings indicate that the inhibition of allergic airway inflammation by G-1 is not dependent on the strain of mouse.
**IL-10 production was enhanced in splenocytes of G-1-treated C57BL/6 mice**

Since GPER has been reported to be associated with increased production of self-regulatory cytokine IL-10 [17,18], we hypothesized that IL-10 plays a pivotal role in G-1-induced anti-inflammatory effects. We first examined IL-10-producing CD4+ T cells and CD8+ T cells from freshly isolated spleens (Fig. 7A). The frequency of IL-10+ CD4+ T cells was significantly higher in G-1-treated mice, although that of IL-10+ CD8+ T cells was comparable (Fig. 7B, C). Foxp3+CD4+ regulatory T (Treg) cells have been shown to negatively regulate allergic airway inflammation through IL-10 [34]. Indeed, the frequency of Foxp3+CD4+ Treg cells was significantly higher in G-1-treated mice (Fig. 7D). Further, splenic GPER+ CD4+ T cells and their IL-10 production were assessed. The frequency of GPER+CD4+ T cells was comparable (Fig. 7E), although G-1-treated mice exhibited a significant increment of IL-10-producing populations in GPER+CD4+ T cells (Fig. 7F). To confirm the upregulated IL-10 production from these cells, the culture supernatants were analyzed using ELISA (Fig. 7D). Indeed, splenic mononuclear cells from G-1-treated mice produced a significantly higher amount of IL-10 as compared with the controls. These data indicate that G-1 enhances the IL-10 production from CD4+ T cell populations.

**Anti-inflammatory effects of G-1 were abolished in IL-10-deficient mice**

Since IL-10 production was upregulated in splenocytes from G-1-treated mice, we examined G-1-treated lung inflammation in IL-10 KO mice with a C57BL/6 background. Histopathological examination demonstrated no significant differences in inflammatory cell accumulation, goblet cell hyperplasia, and lung fibrosis between G-1-treated and non-treated IL-10 KO mice (Fig. 8A, B). In addition, the numbers and types of inflammatory cells in the airways did not differ regardless of G-1 treatment (Fig. 8C).

Concentrations of cytokines (IL-4, 5, and 13 and INF-γ) and a chemokine (eotaxin) in BAL fluid were measured using ELISA. Although IL-5, IL-13, and OVA-specific IgE antibodies were reduced in G-1-treated wild-type mice (Fig. 6A, B), there were no differences in these between G-1-treated and non-treated IL-10 KO mice (Fig. 9A). Moreover, G-1 treatment did not reduce serum levels of total or
OVA-specific IgE in IL-10-deprived mice (Fig. 9B). These findings indicate that the G-1-induced suppressive effect on allergic airway inflammation is dependent on the IL-10 signaling pathway.
Discussion

Understanding the mechanisms by which estrogen influences asthma is of paramount importance, especially for better treatment of female asthmatics. Here, we demonstrated that administration of a GPER-specific agonist during the allergen challenge phase inhibited allergic airway response in two different strains of mice, i.e., those with BALB/c and C57BL/6 background. The effect was associated with increased splenic CD4+ T cells that produce IL-10. IL-10 plays an indispensable role in the effect of G-1, evidenced by the fact that the changes in airway inflammation and cytokine production were not observed in IL-10 KO asthmatic mice. To the best of our knowledge, this is the first demonstration of the involvement of GPER in allergic airway inflammation.

Estrogen in the allergic inflammatory process is a complex phenomenon with both pro- and anti-inflammatory effects. Estradiol can activate the inflammatory cells including mast cells and eosinophils [35,36], although it reduces airway constriction [37,38], down-regulates the production of pro-inflammatory cytokines [39], and protects the cells from harmful oxidative stress [40]. The influence of estrogen on asthma has been investigated in rodent models with exogenous estradiol administration and ovariectomy. The results have shown that estrogen plays unfavorable [7,41], favorable [42], and dual [43] roles in allergic airway inflammatory response. The inconsistency is likely due to different receptors and signaling pathways, which can be altered depending on cell type, and other confounding factors. Recent discovery of GPER and studies using the specific synthetic agonist G-1 and GPER KO mice revealed differential effects of ER and GPER [16]. The current study protocol was aimed at examining the role of GPER activation during the allergen challenge phase using an established asthmatic model.

The improvement of AHR by G-1 is associated with reduced airway inflammation. The direct effect of G-1 on airway smooth muscle cells to induce airway relaxation is not likely, because a recent report indicated no effect of G-1 on tracheal relaxation using ex vivo experiments [37]. The first step of leukocyte migration from the bloodstream into inflamed tissue starts with adhesion to the endothelium by interaction of integrins on leukocytes with upregulated adhesion molecules of the immunoglobulin family, such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1) [44,45]. Leukocytes are subsequently recruited in a stepwise manner involving rolling, activation, firm adhesion, and transmigration from the blood stream into extravascular tissues, further contributing to inflammation. Chakrabarti _et al._ reported that G-1 down-regulated the expression of these adhesion molecules in endothelial cells [45]. GPER-dependent down-regulation of the adhesion molecules provides a possible explanation for suppressed lung inflammation in G-1-treated mice.

The finding that G-1 treatment reduced the production of IL-5 and IL-13 in two different mouse strains is of particular importance because these cytokines have been closely linked to allergic inflammation. IL-5 is the principal cytokine that modulates eosinophil function. During an allergic response, IL-5 stimulates the differentiation of eosinophils from bone marrow cells and maintains cell survival resulting in blood eosinophilia [46]. At the site of inflammation, IL-5 prolongs eosinophil survival, and eosinophils release cytotoxic products including granular proteins and oxygen radicals leading to AHR [47]. IL-13, which shares a receptor component and signaling pathways with IL-4, plays a central role in airway eosinophilia and development of AHR [48]. Since IL-13 directs IgE class-switching in naïve B cells [49], IL-13 likely contributes to decreasing IgE production in G-1-treated mice. In contrast to other Th2 lymphocyte-derived cytokines, IL-4 was not affected by G-1 treatment in this study.

Recently, studies have identified a family of lineage-negative innate lymphoid cells (ILCs). Among them, type 2 ILCs (ILC2) are known to produce abundant amounts of IL-5 and IL-13 in the lung [50,51]. The relationship between ILC2 and GPER is a subject for future study.

IL-10, primarily a Th2 product, is an intrinsic self-regulatory cytokine in allergic conditions [52]. IL-10 has been known to dampen antigen-specific T cell responses such as cytokine production and proliferation [53,54]. Estradiol has been reported to protect against development of experimental autoimmune encephalomyelitis (EAE) in mice by decreasing the production of inflammatory cytokines and increasing IL-10, and through expansion of Treg cells [55,56]. A recent study revealed that GPER played a critical role in increased production of IL-10 in this system [17]. Consistent with two independent reports [18,20], we showed an increase in IL-10 secretion from splenocytes isolated from G-1-treated mice. G-1 has been shown to elicit IL-10 expression in Th17-polarized CD4\(^+\) T cells, increasing the number of IL-10 and IL-17 double positive cells via _de novo_ IL-10 induction [18]. Our current data indicate that systemic
administration of G-1 increases the Treg cells. Indeed, Wang et al. reported that G-1
enhanced suppressive activity of CD4+ Foxp3+ Treg cells through programmed cell
death-1 (PD-1) in a GPER-dependent manner [20]. Although we could not use a
littermate control, the lack of inhibitory effects of G-1 in IL-10 KO mice was clearly
observed. Taken together, GPER activation controls the acute asthmatic condition by
increasing the lymphocyte populations that produce IL-10, resulting in diminished
airway inflammation.

In summary, in the present experimental model of acute asthma, allergic response
was regulated by administration of a GPER-specific agonist. The relative increase in
IL-10 production by extended GPER activation limits the production of allergenic
cytokines such as IL-5 and IL-13, as well as the IgE production and accumulation of
inflammatory cells. The current study provides novel insights into the functional
mechanism of estrogen in asthmatics. Given the implication of GPER, especially in
female reproductive cancer, GPER is now considered to be an important target of drug
development. In this context, the current study also highlights a potential role of GPER
as a novel therapeutic target for future treatments of asthma.

Disclosures
The authors have no financial conflict of interest.
Figure Legends

**Fig. 1.** Experimental protocols and immunofluorescence staining demonstrated GPER expression. Mice were sensitized by two intraperitoneal injections (IP) of OVA/alum and then subjected to three consecutive days of aerosolized OVA challenge (N). To evaluate the effect of G-1 on airway hyperresponsiveness (AHR) and airway inflammation, mice received subcutaneous injections (s.c.) of G-1 (5 µg daily) from Days 27 to 31.

**Fig. 2.** Decreased AHR in G-1-treated asthmatic BALB/c mice. Development of AHR was measured by increased lung resistance (RL, left panel) and decreased dynamic lung compliance (Cdyn, right panel) in response to methacholine. AHR was significantly decreased in G-1-treated mice compared to controls. * P<0.05, ** P<0.01, G-1-treated (n=6) vs. non-treated mice (n=6).

**Fig. 3.** Inflammatory cell accumulation was significantly decreased in G-1-treated mice. A: H&E staining (original magnification: x40 and x400, upper panels) and PAS staining (x400, lower left panel) and MT staining (x400, lower right panel) of serial lung sections. The boxed area of the upper left panel is seen at higher magnification. B: Quantified data of inflammatory cell accumulation, histologically examined in H&E–stained lung tissue, as described in Materials and Methods. C: Inflammatory cell accumulation in BAL fluid. Values are expressed as the mean ± SEM. ** P<0.01, G-1-treated (n=6) vs. non-treated mice (n=6).

**Fig. 4.** Th2 cytokines and IgE were decreased in G-1-treated BALB/c mice compared to non-treated controls. A, B: The levels of eotaxin, IL-4, IL-5, IL-13, and IFN-γ in BAL fluid and total and OVA-specific IgE antibodies in serum of mice were measured using ELISA. The results are expressed as the mean ± SEM. * P<0.05, ** P<0.01, G-1-treated (n=6) vs. non-treated mice (n=6).

**Fig. 5.** Inflammatory cell accumulation was significantly decreased in G-1-treated C57BL/6 mice compared to non-treated controls. A: H&E staining (original magnification: x40 and x400, upper panels) and PAS staining (x400, lower left panel)
and MT staining (x400, lower right panel) of serial lung sections. B: Quantified data of inflammatory cell accumulation, histologically examined in H&E–stained lung tissue, as described in Materials and Methods. C: Inflammatory cell accumulation in BAL fluid. Values are expressed as the mean ± SEM. * P<0.05, ** P<0.01, G-1-treated (n=6) vs. non-treated mice (n=7).

Fig. 6. Th2 cytokines and IgE were decreased in G-1-treated C57BL/6 mice compared to non-treated mice. A, B: The levels of eotaxin, IL-4, IL-5, IL-13, and IFN-γ in BAL fluid and total and OVA-specific IgE antibodies in serum of mice were measured using ELISA. Values are expressed as the mean ± SEM. * P<0.05, ** P<0.01, G-1-treated (n=6) vs. non-treated mice (n=7).

Fig. 7. G-1 treatment increased the frequency of IL-10+CD4+ T cells and the secretion of IL-10 from splenocytes in C57BL/6 mice. A: Representative FACS data showing frequencies of IL-10+CD4+ T cells and IL-10+CD8+ T cells in splenocytes. B, C: Splenocytes were analyzed using a flow cytometer for the frequency of IL-10-producing CD4+ and CD8+ T cells. D: Splenocytes were analyzed using a flow cytometer for the frequency of Foxp3+CD4+ T cells. E, F: Splenocytes were analyzed using a flow cytometer for the frequency of GPER-expressing cells and IL-10-producing GPER+CD4+ T cells. G: The levels of IL-10 in splenocyte culture supernatant were measured by means of ELISA. Values are expressed as the mean ± SEM. * P<0.05, ** P<0.01, G-1-treated (n=6) vs. non-treated mice (n=7).

Fig. 8. IL-10 deprivation abolished G-1-induced improvement of inflammatory cell accumulation in the lung. A: H&E staining (original magnification: x40 and x400, upper panels) and PAS staining (x400, lower left panel) and MT staining (x400, lower right panel) of serial lung sections. B: Quantified data of inflammatory cell accumulation, histologically examined in H&E–stained lung tissue, as described in Materials and Methods. C: Inflammatory cell accumulation in BAL fluid. Values are expressed as the mean ± SEM for G-1-treated mice (n=6) and non-treated controls (n=7).

Fig. 9. IL-10 depletion eradicated G-1-induced reduction of Th2 cytokines in BAL fluid and serum IgE. A, B: The levels of eotaxin, IL-4, IL-5, IL-10, IL-13, and IFN-γ in BAL
fluid and total and OVA-specific IgE antibodies in serum of IL-10 KO mice were measured using ELISA. Values are expressed as the mean ± SEM for G-1-treated mice (n=6) and non-treated controls (n=7).
1 References


33. Martensson UE, Salehi SA, Windahl S, Gomez MF, Sward K, Daszkiewicz-Nilsson


Dimitropoulou C, Drakopanagiotakis F, Chatterjee A, Snead C, Catravas JD (2009) Estrogen replacement therapy prevents airway dysfunction in a murine model of...
allergen-induced asthma. Lung 187: 116-127.


Supporting Information

S1 Fig. Immunofluorescence staining demonstrated GPER expression in asthmatic lung tissue in BALB/c (A) and C57BL/6 (B) mice. The sections were blocked in blocking buffer (3% bovine serum albumin (BSA) in PBS) for 1 hour and incubated with anti-G-protein-coupled estrogen receptor antibodies (GPR30 (N-15)-R: sc-48525-R; rabbit polyclonal, 1:50; SANTA CRUZ, Dallas, TX), diluted in PBS at room temperature for 2 hours. Subsequently, the sections were rinsed in PBS, incubated with Alexa Fluor 488 goat anti-rabbit IgG (1:200, Invitrogen, Grand Island, NY), and counterstained with Hoechst 33342 and trihydrochloride trihydrate (1:5000, Invitrogen). The slides were analyzed using a confocal microscope (Carl Zeiss LSM510). fluorescein isothiocyanate (FITC) (green) was used to visualize GPER, whereas Hoechst 33342 (blue) was used for nuclear staining.